» Articles » PMID: 11982753

Overexpression of IL-4 Alters the Homeostasis in the Skin

Overview
Publisher Elsevier
Specialty Dermatology
Date 2002 May 2
PMID 11982753
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

IL-4 has been implicated to play an important role in the pathogenesis of many inflammatory diseases including skin diseases such as atopic dermatitis. Because it is not clear which pathologic features of atopic dermatitis are dependent on IL-4, we assessed the consequences of IL-4 overexpression in the skin, using transgenic mice overexpressing IL-4 ubiquitously. Although transgenic mice display no clinical signs of skin inflammation, IL-4 induced a wide spectrum of pathologies including an increased number of mast cells and Langerhans cells in dermis and epidermis, respectively, focal deposition of collagen and a considerably reduced adipocyte layer in the dermis as well as an increased mitotic activity of keratinocytes, reflected in acanthosis and hyperkeratosis. The increase in Langerhans cell number may be explained in part by the substantially reduced Langerhans cell emigration from the epidermis in transgenic mice. The molecular mechanism behind this phenomenon remains to be clarified. Under in vitro culture conditions, Langerhans cells from transgenic mice undergo a maturation process similar to that of Langerhans cells from control mice, and their immunostimulatory capacity is also comparable. In contrast, transgenic Langerhans cells are superior to control Langerhans cells in their antigen-processing capacity. We conclude that the overexpression of IL-4 in the skin is, by itself, not sufficient for the induction of a full-blown atopic dermatitis phenotype, but several changes seen in the skin of transgenic mice mirror the cardinal pathologic manifestations of this disease.

Citing Articles

Systematic Review of , , , , , and Gene Polymorphisms and Meta-Analysis of Variant and Its Association with Overweight and Obesity Risk in Men.

Bojarczuk A, Garbacz A, Zekanowski C, Borzemska B, Cieszczyk P, Maculewicz E Int J Mol Sci. 2025; 25(24.

PMID: 39769263 PMC: 11679641. DOI: 10.3390/ijms252413501.


Can aged Abel oil truly be used to treat atopic dermatitis?.

Ouyang X, Yuan Z, Chen X, Gan H, Guo S, Cai J Front Pharmacol. 2024; 15:1449994.

PMID: 39697554 PMC: 11652156. DOI: 10.3389/fphar.2024.1449994.


Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.

Beck L, Cork M, Amagai M, Benedetto A, Kabashima K, Hamilton J JID Innov. 2022; 2(5):100131.

PMID: 36059592 PMC: 9428921. DOI: 10.1016/j.xjidi.2022.100131.


Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab.

Shelton E, Doolittle C, Shinohara M, Thompson J, Moshiri A JAAD Case Rep. 2022; 22:31-33.

PMID: 35274032 PMC: 8904183. DOI: 10.1016/j.jdcr.2022.01.029.


Topical Application of Galgeunhwanggeumhwangryeon-Tang Recovers Skin-Lipid Barrier and Ameliorates Inflammation via Filaggrin-Thymic Stromal Lymphopoietin-Interleukin 4 Pathway.

Ahn S, Shin S, Do Y, Jo Y, Ryu D, Ha K Medicina (Kaunas). 2021; 57(12).

PMID: 34946332 PMC: 8708970. DOI: 10.3390/medicina57121387.